Literature DB >> 29236937

Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it.

V Prasad1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29236937     DOI： 10.1093/annonc/mdx786

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.

Authors:  Julia R Trosman; Michael P Douglas; Su-Ying Liang; Christine B Weldon; Allison W Kurian; Robin K Kelley; Kathryn A Phillips
Journal:  Value Health       Date:  2020-03-19       Impact factor: 5.725

2.  Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application.

Authors:  Gaye Lightbody; Valeriia Haberland; Fiona Browne; Laura Taggart; Huiru Zheng; Eileen Parkes; Jaine K Blayney
Journal:  Brief Bioinform       Date:  2019-09-27       Impact factor: 11.622

3.  Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

Authors:  John Marquart; Emerson Y Chen; Vinay Prasad
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

4.  Precision oncology: separating the wheat from the chaff.

Authors:  Jordi Remon; Rodrigo Dienstmann
Journal:  ESMO Open       Date:  2018-10-30

Review 5.  Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society.

Authors:  Denis Lacombe; Jan Bogaerts; Bertrand Tombal; François Maignen; Leeza Osipienko; Richard Sullivan; Vassilis Golfinopoulos
Journal:  Mol Oncol       Date:  2019-01-19       Impact factor: 6.603

Review 6.  The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology.

Authors:  Margaret Morash; Hannah Mitchell; Himisha Beltran; Olivier Elemento; Jyotishman Pathak
Journal:  J Pers Med       Date:  2018-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.